CA3137365A1 - Formulations et anticorps anti-cd38 - Google Patents

Formulations et anticorps anti-cd38 Download PDF

Info

Publication number
CA3137365A1
CA3137365A1 CA3137365A CA3137365A CA3137365A1 CA 3137365 A1 CA3137365 A1 CA 3137365A1 CA 3137365 A CA3137365 A CA 3137365A CA 3137365 A CA3137365 A CA 3137365A CA 3137365 A1 CA3137365 A1 CA 3137365A1
Authority
CA
Canada
Prior art keywords
amino acid
antibody
seq
acid sequence
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3137365A
Other languages
English (en)
Inventor
Beatrice Cameron
Marielle CHIRON BLONDEL
Jacques Dumas
Alain Fournier
Jonathan KINGSBURY
Cendrine Lemoine
Brian Murray
Nathan OSTBERG
Sanket PATKE
Angela VIRONE-ODDOS
Zichuan ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of CA3137365A1 publication Critical patent/CA3137365A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

L'invention concerne des anticorps qui se lient spécifiquement au CD38 humain, des formulations et des formes posologiques unitaires comprenant les anticorps, des procédés de préparation de ces anticorps et des procédés d'utilisation de ces anticorps.
CA3137365A 2019-04-23 2020-04-23 Formulations et anticorps anti-cd38 Pending CA3137365A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962837518P 2019-04-23 2019-04-23
US62/837,518 2019-04-23
US201962859699P 2019-06-10 2019-06-10
US62/859,699 2019-06-10
EP20305145 2020-02-17
EP20305146.1 2020-02-17
EP20305146 2020-02-17
EP20305145.3 2020-02-17
PCT/US2020/029531 WO2020219681A1 (fr) 2019-04-23 2020-04-23 Formulations et anticorps anti-cd38

Publications (1)

Publication Number Publication Date
CA3137365A1 true CA3137365A1 (fr) 2020-10-29

Family

ID=70739160

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3137365A Pending CA3137365A1 (fr) 2019-04-23 2020-04-23 Formulations et anticorps anti-cd38

Country Status (14)

Country Link
EP (1) EP3958898A1 (fr)
JP (1) JP2022529502A (fr)
KR (1) KR20220003562A (fr)
CN (1) CN114269375A (fr)
AU (1) AU2020261039A1 (fr)
BR (1) BR112021021060A2 (fr)
CA (1) CA3137365A1 (fr)
CO (1) CO2021015462A2 (fr)
IL (1) IL287477A (fr)
MA (1) MA55761A (fr)
MX (1) MX2021012967A (fr)
SG (1) SG11202111602YA (fr)
TW (1) TW202104269A (fr)
WO (1) WO2020219681A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024023843A1 (fr) * 2022-07-26 2024-02-01 Dr. Reddy’S Laboratories Limited Formulation pharmaceutique d'un anticorps thérapeutique et ses préparations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2921500T (pt) 2004-07-10 2023-09-25 The Institute For Cancer Res Linhas de células assassinas naturais humanas modificadas geneticamente
EP1914242A1 (fr) * 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer

Also Published As

Publication number Publication date
SG11202111602YA (en) 2021-11-29
EP3958898A1 (fr) 2022-03-02
JP2022529502A (ja) 2022-06-22
IL287477A (en) 2021-12-01
CO2021015462A2 (es) 2021-12-10
MA55761A (fr) 2022-03-02
MX2021012967A (es) 2022-01-18
AU2020261039A1 (en) 2021-12-09
KR20220003562A (ko) 2022-01-10
CN114269375A (zh) 2022-04-01
BR112021021060A2 (pt) 2021-12-14
TW202104269A (zh) 2021-02-01
WO2020219681A1 (fr) 2020-10-29

Similar Documents

Publication Publication Date Title
US20230416395A1 (en) Anti-cd38 antibodies and formulations
CN110914306B (zh) 检查点抑制物双特异性抗体
US10053517B2 (en) Hybrid constant regions
US11008403B2 (en) Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
US8952134B2 (en) Hybrid constant regions
US9540442B2 (en) Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
AU2009231991B2 (en) HER2/neu-specific antibodies and methods of using same
AU2018250301A1 (en) Anti-ICOS agonist antibodies and uses thereof
US10501552B2 (en) Multivalent molecules comprising DR5-binding domains
CA2935423A1 (fr) Molecules d'anticorps anti-pd-1 et leurs utilisations
AU2006334552A1 (en) Method for preparing antibodies selective for activating Fc receptors
US11926667B2 (en) Bioengineered T cell mediated immunity, materials and other methods for modulating cluster of differentiation IV and/or VIII
AU2020412595A1 (en) Therapy for the treatment of cancer
KR20240035758A (ko) 조작된 폴리펩타이드
CA3137365A1 (fr) Formulations et anticorps anti-cd38
JP7368007B2 (ja) 免疫関連疾患の予防または治療用組成物
AU2022288574A9 (en) Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2
US20220306734A1 (en) Anti-mglur5 antibodies and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220110

EEER Examination request

Effective date: 20220110

EEER Examination request

Effective date: 20220110

EEER Examination request

Effective date: 20220110

EEER Examination request

Effective date: 20220110